Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 489,983
  • Shares Outstanding, K 79,672
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,350 K
  • EBIT $ -181 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Options Overview Details

View History
  • Implied Volatility 105.93% (+10.61%)
  • Historical Volatility 57.41%
  • IV Percentile 7%
  • IV Rank 5.88%
  • IV High 737.60% on 02/13/26
  • IV Low 66.45% on 09/02/25
  • Expected Move (DTE 10) 1.23 (20.04%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 777
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,457
  • Open Int (30-Day) 2,302
  • Expected Range 4.92 to 7.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.59
  • Number of Estimates 1
  • High Estimate -0.59
  • Low Estimate -0.59
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -47.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.04 +52.23%
on 02/11/26
6.18 -0.49%
on 03/09/26
+2.01 (+48.55%)
since 02/09/26
3-Month
3.11 +98.07%
on 12/19/25
6.18 -0.49%
on 03/09/26
+3.01 (+95.86%)
since 12/09/25
52-Week
2.45 +150.51%
on 05/15/25
6.18 -0.49%
on 03/09/26
+3.16 (+105.69%)
since 03/07/25

Most Recent Stories

More News
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American  C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Show Bemnifosbuvir Has Unique...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 6.15 (+4.41%)
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 6.15 (+4.41%)

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 6.73
2nd Resistance Point 6.45
1st Resistance Point 6.30
Last Price 6.15
1st Support Level 5.88
2nd Support Level 5.60
3rd Support Level 5.45

See More

52-Week High 6.18
Last Price 6.15
Fibonacci 61.8% 4.76
Fibonacci 50% 4.32
Fibonacci 38.2% 3.88
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar